Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial.

Gharebaghi, Naser; Nejadrahim, Rahim; Mousavi, Seyed Jalil; Sadat-Ebrahimi, Seyyed-Reza; Hajizadeh, Reza

Gharebaghi, Naser; Nejadrahim, Rahim; Mousavi, Seyed Jalil; Sadat-Ebrahimi, Seyyed-Reza; Hajizadeh, Reza.

Gharebaghi N; Department of Infectious Diseases, Urmia University of Medical Sciences, Urmia, Iran.
Nejadrahim R; Department of Infectious Diseases, Urmia University of Medical Sciences, Urmia, Iran.
Mousavi SJ; Department of Infectious Diseases, Urmia University of Medical Sciences, Urmia, Iran.
Sadat-Ebrahimi SR; Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Sadatr@tbzmed.ac.ir.
Hajizadeh R; Department of Cardiology, Urmia University of Medical Sciences, Urmia, Iran. hajizadh.reza@gmail.com.

BMC Infect Dis ; 20(1): 895, 2020 Nov 26.

Article in English | MEDLINE | ID: covidwho-992449

ABSTRACT

ABSTRACT

An amendment to this paper has been published and can be accessed via the original article.

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Language: English Journal: BMC Infect Dis Journal subject: Communicable Diseases Year: 2020 Document Type: Article Affiliation country: S12879-020-05628-w

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google